Literature DB >> 24075223

From the Medical Board of the National Psoriasis Foundation: Vaccination in adult patients on systemic therapy for psoriasis.

Lara Wine-Lee1, Sara C Keller, Marissa B Wilck, Stephen J Gluckman, Abby S Van Voorhees.   

Abstract

Patients with moderate to severe psoriasis often require systemic immunomodulatory medications that place them at risk for infection. Vaccination is a proven strategy to reduce infections. However, vaccination rates among patients with inflammatory autoimmune conditions, including psoriasis, remain low. We review the literature regarding vaccine-preventable illness and vaccinations commonly used in the United States in patients older than 18 years on immunosuppressive therapies that are used in the treatment of psoriasis. The medical board of the National Psoriasis Foundation recommends that dermatologists counsel patients on updating vaccinations in accordance with recommendations of the Advisory Committee for Immunization Practices as any measures taken to prevent infection can increase the safety of immunomodulatory therapies.
Copyright © 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  CDC; Centers for Disease Control and Prevention; HBV; HPV; IBD; IL; MMR; TNF; biologics; cyclosporine; hepatitis B virus; human papillomavirus; immunosuppressive therapy; inactivated vaccine; inflammatory bowel disease; interleukin; live vaccine; measles, mumps, and rubella; methotrexate; tumor necrosis factor; vaccine administration; vaccine counseling

Mesh:

Substances:

Year:  2013        PMID: 24075223     DOI: 10.1016/j.jaad.2013.06.046

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  [Insufficient tetanus vaccination protection in psoriasis and systemic immunosuppression : Results of a retrospective investigation of 101 patients].

Authors:  W Sondermann; L Leister; N Rompoti; J Dissemond; J Klode; A Körber
Journal:  Hautarzt       Date:  2018-11       Impact factor: 0.751

3.  Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom.

Authors:  Junko Takeshita; Daniel B Shin; Alexis Ogdie; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2018-03-02       Impact factor: 8.551

4.  [Guidelines for vaccination of immunocompromised individuals].

Authors:  Ursula Wiedermann; Harald H Sitte; Heinz Burgmann; Alexander Eser; Petra Falb; Heidemarie Holzmann; Maria Kitchen; Marcus Köller; Herwig Kollaritsch; Michael Kundi; Hans Lassmann; Ingomar Mutz; Winfried F Pickl; Elisabeth Riedl; Maria Sibilia; Florian Thalhammer; Barbara Tucek; Werner Zenz; Karl Zwiauer
Journal:  Wien Klin Wochenschr       Date:  2016-07-25       Impact factor: 1.704

Review 5.  Psoriasis and comorbid diseases: Implications for management.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

6.  Bulky Condyloma Acuminata following Ustekinumab Treatment for Plaque Psoriasis: A Case Report.

Authors:  Martina Burlando; Mattia Fabio Molle; Emanuele Cozzani; Aurora Parodi
Journal:  Case Rep Dermatol       Date:  2021-04-21

7.  Estimated Public Health Impact of the Recombinant Zoster Vaccine.

Authors:  Brandon J Patterson; Philip O Buck; Desmond Curran; Desirée Van Oorschot; Justin Carrico; William L Herring; Yuanhui Zhang; Jeffrey J Stoddard
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-05-26

8.  Possible Triggering Effect of Influenza Vaccination on Psoriasis.

Authors:  Ali Tahsin Gunes; Emel Fetil; Sevgi Akarsu; Ozlem Ozbagcivan; Lale Babayeva
Journal:  J Immunol Res       Date:  2015-08-25       Impact factor: 4.818

9.  Response to Tetanus and Pneumococcal Vaccination Following Administration of Ixekizumab in Healthy Participants.

Authors:  Elisa V Gomez; Jessie L Bishop; Kimberley Jackson; Talia M Muram; Diane Phillips
Journal:  BioDrugs       Date:  2017-12       Impact factor: 5.807

10.  Occurrence of an invasive cervical epidermoid carcinoma in a patient receiving TNF-α blocking therapy for hidradenitis suppurativa.

Authors:  Aurélie Ram; Jean-Christophe Noël; Véronique Del Marmol; Farida Benhadou
Journal:  JAAD Case Rep       Date:  2018-10-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.